Elizabeth J Phillips

Summary

Affiliation: Murdoch University
Country: Australia

Publications

  1. ncbi Pharmacogenetics and the potential for the individualization of antiretroviral therapy
    Elizabeth J Phillips
    Centre for Clinical Pharmacology and Infectious Diseases, Royal Perth Hospital, Murdoch University, Perth, Australia
    Curr Opin Infect Dis 21:16-24. 2008
  2. ncbi Drug hypersensitivity: pharmacogenetics and clinical syndromes
    Elizabeth J Phillips
    Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
    J Allergy Clin Immunol 127:S60-6. 2011
  3. ncbi Pharmacogenetics of drug hypersensitivity
    Elizabeth J Phillips
    Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Australia
    Pharmacogenomics 11:973-87. 2010
  4. ncbi Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir
    Elizabeth J Phillips
    Divisions of Clinical Pharmacology, Infectious Diseases and Drug Safety Clinic, Sunnybrook and Women's Health Sciences Centre, University of Toronto, Ontario, Canada
    AIDS 16:2223-5. 2002
  5. ncbi A review of drug patch testing and implications for HIV clinicians
    Neil H Shear
    Dermatology and the Drug Safety Clinic, Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    AIDS 22:999-1007. 2008
  6. ncbi Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Elizabeth J Phillips
    Clin Infect Dis 43:103-5. 2006
  7. ncbi A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase
    Celia K S Chui
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 44:1503-8. 2007
  8. ncbi Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients
    Tony Antoniou
    St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Ther Drug Monit 27:779-81. 2005
  9. ncbi Comment: Sulfonamide cross-reactivity: fact or fiction?
    Elizabeth J Phillips
    Ann Pharmacother 39:1372-3; author reply 1373. 2005
  10. ncbi Clinical and immunogenetic correlates of abacavir hypersensitivity
    Elizabeth J Phillips
    British Columbia Centre for Excellence in HIV/AIDS, Vancouver, University of British Columbia, Canada
    AIDS 19:979-81. 2005

Collaborators

Detail Information

Publications17

  1. ncbi Pharmacogenetics and the potential for the individualization of antiretroviral therapy
    Elizabeth J Phillips
    Centre for Clinical Pharmacology and Infectious Diseases, Royal Perth Hospital, Murdoch University, Perth, Australia
    Curr Opin Infect Dis 21:16-24. 2008
    ....
  2. ncbi Drug hypersensitivity: pharmacogenetics and clinical syndromes
    Elizabeth J Phillips
    Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
    J Allergy Clin Immunol 127:S60-6. 2011
    ..International collaborative consortia have been formed with the goal of developing phenotypic standardization and undertaking HLA and genome-wide analyses in diverse populations with these syndromes...
  3. ncbi Pharmacogenetics of drug hypersensitivity
    Elizabeth J Phillips
    Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Australia
    Pharmacogenomics 11:973-87. 2010
    ..HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world...
  4. ncbi Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir
    Elizabeth J Phillips
    Divisions of Clinical Pharmacology, Infectious Diseases and Drug Safety Clinic, Sunnybrook and Women's Health Sciences Centre, University of Toronto, Ontario, Canada
    AIDS 16:2223-5. 2002
  5. ncbi A review of drug patch testing and implications for HIV clinicians
    Neil H Shear
    Dermatology and the Drug Safety Clinic, Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    AIDS 22:999-1007. 2008
  6. ncbi Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Elizabeth J Phillips
    Clin Infect Dis 43:103-5. 2006
  7. ncbi A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase
    Celia K S Chui
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 44:1503-8. 2007
    ....
  8. ncbi Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients
    Tony Antoniou
    St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Ther Drug Monit 27:779-81. 2005
    ..No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary...
  9. ncbi Comment: Sulfonamide cross-reactivity: fact or fiction?
    Elizabeth J Phillips
    Ann Pharmacother 39:1372-3; author reply 1373. 2005
  10. ncbi Clinical and immunogenetic correlates of abacavir hypersensitivity
    Elizabeth J Phillips
    British Columbia Centre for Excellence in HIV/AIDS, Vancouver, University of British Columbia, Canada
    AIDS 19:979-81. 2005
    ..001). Five of seven PT (71%) versus one of 11 controls (9%) (P = 0.005) showed significant abacavir-specific CD8 proliferation, suggesting a direct role for HLA-B*5701-restricted CD8 cells in the pathophysiology of AHS...
  11. ncbi The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum
    Rolf P G van Heeswijk
    Division of Incectious Diseases and Department of Pharmacy, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada
    Clin Pharmacol Ther 76:588-97. 2004
    ..The objective of this study was to explore the pharmacokinetics of nelfinavir and its active metabolite hydroxy-t-butylamidenelfinavir (M8) during pregnancy and post partum...
  12. ncbi Challenges of adherence management in human immunodeficiency virus pharmacotherapy
    Laura Y Park-Wyllie
    Inner City Health Research Unit, St Michael's Hospital
    Can J Clin Pharmacol 10:189-95. 2003
    ....
  13. ncbi Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein?
    Elizabeth J Phillips
    AIDS 17:1577-8. 2003
  14. ncbi Cutaneous manifestations of antiviral therapy
    Elizabeth J Phillips
    J Am Acad Dermatol 48:985-6. 2003
  15. ncbi Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals
    Manuela G Neuman
    Department of Pharmacology, University of Toronto, Canada
    Ther Drug Monit 24:728-36. 2002
    ..Larger patient populations, as well as in vitro studies are needed to further address the reasons for elevated results in immunocompromised patients and to validate the usefulness of the test...
  16. ncbi The chronicles of HIV therapeutics: where to begin, when to start and how will it end--a tale of two decades and beyond?
    Elizabeth J Phillips
    Division of Clinical Pharmacology and Infectious Diseases, Sunnybrook Women's College Health Sciences Centre, Toronto, Ontario, Canada
    Can J Clin Pharmacol 9:120-2. 2002
  17. ncbi Efavirenz-induced skin eruption and successful desensitization
    Elizabeth J Phillips
    Clinical Pharmacology and Infectious Diseases, Sunnybrook and Women s Health Sciences Centre, Drug Safety Clinic, Toronto, Ontario, Canada
    Ann Pharmacother 36:430-2. 2002
    ..To report a patient with efavirenz-induced hypersensitivity syndrome reaction who was successfully desensitized to efavirenz...